Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (9115)	9/11/2003 6:01:07 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

Mike >>Very, very rarely does the FDA approve drugs when primary end points are not met.>> That is no doubt the case. In defense of GNTA it should however be pointed out, that all patients have not yet become events. When the study is concluded the results will look different. The question is: How different? Why did they issue the PR? I suppose they had to. The un-blinding was predefined and once the results were available they shouldn't really keep them under wraps - regardless if they were good, bad or just confusing. Erik